NASDAQ: ASMBAssembly Biosciences Inc Stock
$1.11+0.15 (+15.63%)
Updated Jun 2, 2023
ASMB Price
$1.11
Fair Value Price
$2.19
Market Cap
$57.85M
52 Week Low
$0.77
52 Week High
$2.42
P/E
-0.61x
P/B
0.82x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$88.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$80M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ASMB Overview
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ASMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASMB ($1.11) is undervalued by 49.38% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ASMB ($1.11) is significantly undervalued by 49.38% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ASMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ASMB due diligence checks available for Premium users.
Be the first to know about important ASMB news, forecast changes, insider trades & much more!
ASMB News
Valuation
ASMB fair value
Fair Value of ASMB stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$2.19
Undervalued by
49.38%
ASMB ($1.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ASMB ($1.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ASMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ASMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.61x
Industry
11.51x
Market
52.69x
ASMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
5.2x
ASMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASMB's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.0M
Profit Margin
0%
ASMB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$83.1M
Liabilities
$12.8M
Debt to equity
0.18
ASMB's short-term assets ($79.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASMB's short-term assets ($79.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASMB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.4M
Investing
$10.0M
Financing
$4.5M
ASMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASMB vs Biotech Stocks
Assembly Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.